SCHEMBL933152

SCHEMBL933152

CCCCCCCCCCCCCC(=O)CC(CCCC(=O)O)C(=O)CCCCCCCCCCCCC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.59
MAPT P10636 2/20 0.59
GPR84 Q9NQS5 7/20 0.55
PPARG P37231 7/20 0.55
PPARD Q03181 7/20 0.55
PPARA Q07869 7/20 0.55
HDAC11 Q96DB2 5/20 0.55
TSHR P16473 4/20 0.55
PTPN1 P18031 3/20 0.55
FABP4 P15090 3/20 0.55
ALDH1A1 P00352 2/20 0.55
TLR2 O60603 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
FFAR1 O14842 2/20 0.55
FFAR4 Q5NUL3 2/20 0.55
ALOX15 P16050 2/20 0.55
HSD17B10 Q99714 2/20 0.55
SLC22A6 Q4U2R8 1/20 0.55
SLC22A8 Q8TCC7 1/20 0.55
MEN1 O00255 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047699 0.97 KMT2A (0.59) KMT2AMAPTGPR84PPARGPPARD
SCHEMBL1047282 0.97 KMT2A (0.59) KMT2AMAPTGPR84PPARGPPARD
SCHEMBL933570 0.92 KMT2A (0.56) KMT2AMAPTGPR84PPARGPPARD
SCHEMBL934023 0.92 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL934025 0.92 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL933504 0.89 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL933503 0.89 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL933601 0.89 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL933603 0.89 PPARG (0.62) KMT2AMAPTPPARGPPARDPPARA
SCHEMBL8002202 0.86 FFAR4 (0.65) KMT2AMAPTGPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734964-A1 LIPID PARTICLES FOR DELIVERING A PAYLOAD Repertoire Immune Medicines, Inc. (US) 2026-05-06 EP claimed
WO-2025007024-A1 LIPID PARTICLES FOR DELIVERING A PAYLOAD Repertoire Immune Medicines, Inc. (US) 2025-01-02 WO claimed
US-20160151282-A1 AMPHOTERIC LIPOSOME FORMULATIONS MARINA BIOTECH INC (US) 2016-06-02 US claimed
US-9283186-B2 Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome MARINA BIOTECH, INC. (US) 2016-03-15 US claimed
EP-4734964-A1 LIPID PARTICLES FOR DELIVERING A PAYLOAD Repertoire Immune Medicines, Inc. (US) 2026-05-06 EP disclosed
EP-4727969-A2 METHODS FOR PROVIDING INTERCELLULAR COMMUNICATION Rethink64 Bionetworks PBC (US) 2026-04-22 EP disclosed
WO-2025007024-A1 LIPID PARTICLES FOR DELIVERING A PAYLOAD Repertoire Immune Medicines, Inc. (US) 2025-01-02 WO disclosed
WO-2024259374-A2 METHODS FOR PROVIDING INTERCELLULAR COMMUNICATION RETHINK64 BIONETWORKS PBC (US) 2024-12-19 WO disclosed
US-20240389602-A1 LIPOSOME FORMULATIONS FOR PESTICIDE DELIVERY AND METHODS FOR PRODUCING AND USING THE SAME SUTERRA LLC 2024-11-28 US disclosed
US-11541010-B2 Amphoteric liposomes comprising imino lipids BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2023-01-03 US disclosed
US-20200330384-A1 AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2020-10-22 US disclosed
EP-2823810-B9 Amphoteric liposomes comprising imino lipids NOVOSOM VERWALTUNGS GMBH (DE) 2019-10-30 EP disclosed
EP-2125031-A2 LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS Novosom AG (DE) 2009-12-02 EP disclosed
EP-2094238-A2 IMPROVEMENTS IN OR RELATING TO AMPHOTERIC LIPOSOMES Novosom AG (DE) 2009-09-02 EP disclosed
WO-2009047006-A2 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS NOVOSOM AG (DE) 2009-04-16 WO disclosed
WO-2008155141-A2 NOVEL FACULTATIVE CATONIC STEROLS NOVOSOM AG (DE) 2008-12-24 WO disclosed
US-20080306153-A1 Lipids and lipid assemblies comprising transfection enhancer elements CEQUENT PHARMACEUTICALS, INC. 2008-12-11 US disclosed
WO-2008074487-A2 LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS NOVOSOM AG (DE) 2008-06-26 WO disclosed
WO-2008043575-A2 IMPROVEMENTS IN OR RELATING TO AMPHOTERIC LIPOSOMES NOVOSOM AG (DE) 2008-04-17 WO disclosed
US-20080089932-A1 Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome MARINA BIOTECH, INC. 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541010-B2 Amphoteric liposomes comprising imino lipids SGMS1, SGMS2, PHOSPHO1 KMT2A 3600/4885MAPT 4693/4885GPR84 1601/4885
US-20080306153-A1 Lipids and lipid assemblies comprising transfection enhancer elements SREBF1, SREBF2, ELOVL1 KMT2A 2437/4885MAPT 4673/4885GPR84 3559/4885
US-20200330384-A1 AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS SGMS1, SGMS2, PHOSPHO1 KMT2A 3600/4885MAPT 4693/4885GPR84 1601/4885
US-20160151282-A1 AMPHOTERIC LIPOSOME FORMULATIONS LIPA, SGMS1, SGMS2 KMT2A 2418/4885MAPT 3559/4885GPR84 4002/4885
US-20080089932-A1 Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome LIPA, SGMS1, SGMS2 KMT2A 3311/4885MAPT 3461/4885GPR84 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.